PMR-116 is under clinical development by Pimera and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how PMR-116’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
PMR-116 is under development for the treatment of metastatic solid tumor, acute myelocytic leukemia, metastatic breast cancer, osteosarcoma, multiple myeloma and B-cell lymphoma. The drug candidate is a small molecule second generation RNA polymerase I inhibitor. It is administered through oral route.
Pimera is a US-based provider of technology services.
For a complete picture of PMR-116’s drug-specific PTSR and LoA scores, buy the report here.